{
  "chapters": [
    {
      "number": 1,
      "title": "Intro",
      "durationSec": 33,
      "positionSec": 0
    },
    {
      "number": 2,
      "title": "Begrüßung",
      "durationSec": 172,
      "positionSec": 33
    },
    {
      "number": 3,
      "title": "Inzidenzen",
      "durationSec": 414,
      "positionSec": 205
    },
    {
      "number": 4,
      "title": "Sterblichkeit",
      "durationSec": 536,
      "positionSec": 620
    },
    {
      "number": 5,
      "title": "Altersverteilung",
      "durationSec": 601,
      "positionSec": 1156
    },
    {
      "number": 6,
      "title": "Bundesländer",
      "durationSec": 296,
      "positionSec": 1757
    },
    {
      "number": 7,
      "title": "Tests und Positivquote",
      "durationSec": 187,
      "positionSec": 2054
    },
    {
      "number": 8,
      "title": "Impfkampagne in Deutschland",
      "durationSec": 698,
      "positionSec": 2241
    },
    {
      "number": 9,
      "title": "Delta",
      "durationSec": 443,
      "positionSec": 2940
    },
    {
      "number": 10,
      "title": "Varianten international",
      "durationSec": 164,
      "positionSec": 3383
    },
    {
      "number": 11,
      "title": "Cubas Impfstoff",
      "durationSec": 347,
      "positionSec": 3548
    },
    {
      "number": 12,
      "title": "BioNTech Quartalsergebnisse",
      "durationSec": 252,
      "positionSec": 3895
    },
    {
      "number": 13,
      "title": "Zukunft der mRNA Technologie",
      "durationSec": 623,
      "positionSec": 4147
    },
    {
      "number": 14,
      "title": "10 Thesen zur Impfung",
      "durationSec": 558,
      "positionSec": 4771
    },
    {
      "number": 15,
      "title": "Wie geht es weiter?",
      "durationSec": 2258,
      "positionSec": 5329
    },
    {
      "number": 16,
      "title": "Fazit",
      "durationSec": 314,
      "positionSec": 7587
    },
    {
      "number": 17,
      "title": "Bonus Track",
      "durationSec": 183,
      "positionSec": 7902
    }
  ]
}